A short course of darolutamide (Nubeqa) enhanced the imaging signal of prostate-specific membrane antigen (PSMA)-PET in a ...

Where previous research showed that PSMA therapy for prostate cancer can prolong the lives of patients who have exhausted all ...

Investigators developed and validated new PSMA-PET-based nomograms for prognostication across prostate cancer stages to help ...

The 2026 PSMA & Beyond conference featured a clinical development session and presentation by Dr. Jeremie Calais discussing a review of phase 1/2 compounds recently published. Without question, there ...

India, April 2 -- Men with early-stage metastatic prostate cancer may soon be able to postpone the debilitating side effects ...

The study published by Bastiaan M Privé and colleagues in The Lancet Oncology represents, to our knowledge, the first randomised phase 2 trial evaluating lutetium-177–PSMA-617 (177Lu-PSMA-617) in ...

Clarity Pharmaceuticals (ASX: CU6) (Clarity or Company), a clinical-stage radiopharmaceutical company with a mission to ...

A randomized study in 58 men with limited metastatic prostate cancer found that PSMA therapy postponed the need for hormone ...

Tagawa, MD, identified 3 primary clinical scenarios where PSMA PET scans have become the established standard for prostate cancer care. The first application is initial s ...

Whereas it may appear that Ac-PSMA has had a slower development trajectory compared to Lu-PSMA radioligand therapy, Dr. Eiber ...

Telix Pharmaceuticals (NASDAQ:TLX) executives highlighted commercial momentum in prostate cancer imaging and outlined ...